Sandra J. Casak

1.5k total citations
32 papers, 1.0k citations indexed

About

Sandra J. Casak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sandra J. Casak has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Sandra J. Casak's work include Colorectal Cancer Treatments and Studies (7 papers), Ocular Oncology and Treatments (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Sandra J. Casak is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Ocular Oncology and Treatments (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Sandra J. Casak collaborates with scholars based in United States, Argentina and Italy. Sandra J. Casak's co-authors include Guillermo Chantada, Steven J. Lemery, Richard Pazdur, Elsa Raslawski, Enrique Schvartzman, Julio Manzitti, Adriana Fandiño, Lola A. Fashoyin‐Aje, Marc R. Theoret and Kirsten B. Goldberg and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Sandra J. Casak

32 papers receiving 987 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra J. Casak United States 18 455 238 215 189 171 32 1.0k
Martha M. Kirstein Germany 19 384 0.8× 54 0.2× 270 1.3× 423 2.2× 178 1.0× 65 1.2k
Andreas Marinelli Netherlands 21 1.1k 2.4× 56 0.2× 279 1.3× 914 4.8× 123 0.7× 47 1.5k
Steven Blotner United States 17 598 1.3× 25 0.1× 223 1.0× 125 0.7× 257 1.5× 36 1.1k
Ilaria Panzini Italy 17 286 0.6× 32 0.1× 299 1.4× 317 1.7× 75 0.4× 35 1.0k
Timothée Olivier Switzerland 15 463 1.0× 51 0.2× 341 1.6× 64 0.3× 123 0.7× 83 873
R Castan France 4 829 1.8× 31 0.1× 392 1.8× 117 0.6× 200 1.2× 6 1.0k
Su Jin Heo South Korea 16 553 1.2× 16 0.1× 333 1.5× 220 1.2× 188 1.1× 38 904
Reury-Perng Perng Taiwan 20 598 1.3× 24 0.1× 748 3.5× 128 0.7× 164 1.0× 51 1.1k
Tracy Proverbs‐Singh United States 7 688 1.5× 11 0.0× 268 1.2× 116 0.6× 210 1.2× 14 1.1k
Francesca Elice Italy 17 440 1.0× 16 0.1× 126 0.6× 102 0.5× 455 2.7× 32 1.2k

Countries citing papers authored by Sandra J. Casak

Since Specialization
Citations

This map shows the geographic impact of Sandra J. Casak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra J. Casak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra J. Casak more than expected).

Fields of papers citing papers by Sandra J. Casak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra J. Casak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra J. Casak. The network helps show where Sandra J. Casak may publish in the future.

Co-authorship network of co-authors of Sandra J. Casak

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra J. Casak. A scholar is included among the top collaborators of Sandra J. Casak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra J. Casak. Sandra J. Casak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Casak, Sandra J., Vaibhav Kumar, Chi Song, et al.. (2024). FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer. Clinical Cancer Research. 30(16). 3371–3377. 7 indexed citations
2.
Pinato, David J., Xiaoxue Li, Pallavi S. Mishra‐Kalyani, et al.. (2023). Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Reports. 5(6). 100747–100747. 33 indexed citations
3.
Gandhy, Shruti U., Sandra J. Casak, Sirisha L. Mushti, et al.. (2023). FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements. Clinical Cancer Research. 29(20). 4027–4031. 11 indexed citations
4.
Horiba, M. Naomi, Sandra J. Casak, Pallavi S. Mishra‐Kalyani, et al.. (2022). FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease. Clinical Cancer Research. 28(24). 5244–5248. 7 indexed citations
5.
Pinato, David J., Xiaoxue Li, Pallavi S. Mishra‐Kalyani, et al.. (2022). Antibiotic therapy and association with oncological outcomes from targeted and immune-based therapy in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 40(16_suppl). 4089–4089. 4 indexed citations
6.
Saung, May Tun, Lorraine Pelosof, Sandra J. Casak, et al.. (2021). FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. The Oncologist. 26(9). 797–806. 77 indexed citations
7.
8.
Pelosof, Lorraine, Steven J. Lemery, Sandra J. Casak, et al.. (2018). Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. The Oncologist. 23(4). 496–500. 15 indexed citations
9.
Jarow, Jonathan P., Sandra J. Casak, Meredith K. Chuk, Lori A. Ehrlich, & Sean Khozin. (2016). The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative. Clinical Cancer Research. 22(9). 2111–2113. 17 indexed citations
10.
He, Kun, Huanyu Chen, Thomas Gwise, et al.. (2016). Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study. Clinical Cancer Research. 22(21). 5167–5170. 8 indexed citations
11.
Casak, Sandra J., Steven J. Lemery, Yuan Li Shen, et al.. (2011). U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia. The Oncologist. 16(1). 97–104. 32 indexed citations
12.
Chantada, Guillermo, Adriana Fandiño, Elsa Raslawski, et al.. (2004). Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatric Blood & Cancer. 44(5). 455–460. 40 indexed citations
13.
Chantada, Guillermo, Adriana Fandiño, María Teresa García de Dávila, et al.. (2004). Results of a prospective study for the treatment of retinoblastoma. Cancer. 100(4). 834–842. 56 indexed citations
14.
Chantada, Guillermo, et al.. (2004). Activity of topotecan in retinoblastoma. Ophthalmic Genetics. 25(1). 37–43. 40 indexed citations
15.
Chantada, Guillermo, Sandra J. Casak, Daniel Alderete, et al.. (2003). Treatment of B‐cell malignancies in children with a modified BFM‐NHL 90 protocol in argentina. Medical and Pediatric Oncology. 41(5). 488–490. 10 indexed citations
16.
Casak, Sandra J., et al.. (2002). Paediatric oncology in Argentina: medical and ethical issues. The Lancet Oncology. 3(2). 111–117. 17 indexed citations
17.
Chantada, Guillermo, María Teresa García de Dávila, Adriana Fandiño, et al.. (1999). Retinoblastoma with low risk for extraocular relapse. Ophthalmic Genetics. 20(3). 133–140. 21 indexed citations
18.
Chantada, Guillermo, et al.. (1999). Phase II Window of Idarubicin in Children With Extraocular Retinoblastoma. Journal of Clinical Oncology. 17(6). 1847–1847. 17 indexed citations
19.
Zubizarreta, Pedro, Marı́a Sara Felice, Elizabeth M. Alfaro, et al.. (1998). Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy. Leukemia Research. 22(5). 465–472. 22 indexed citations
20.
Sackmann‐Muriel, Federico, Pedro Zubizarreta, Guillermo Gallo, et al.. (1997). Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina. Medical and Pediatric Oncology. 29(6). 544–552. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martha M. Kirstein Breakdown of academic impact, for papers by Andreas Marinelli Breakdown of academic impact, for papers by Steven Blotner Breakdown of academic impact, for papers by Ilaria Panzini Breakdown of academic impact, for papers by Timothée Olivier Breakdown of academic impact, for papers by R Castan Breakdown of academic impact, for papers by Su Jin Heo Breakdown of academic impact, for papers by Reury-Perng Perng Breakdown of academic impact, for papers by Tracy Proverbs‐Singh Breakdown of academic impact, for papers by Francesca Elice
Rankless by CCL
2026